



Investor Contact:
Stephanie Carrington /David Burke
The Ruth Group
(646) 536 -7017 / 7009
scarrington@theruthgroup.com
dburke@theruthgroup.com

Media Contacts:
Aaron Estrada
The Ruth Group
(646) 536 -7028
aestrada@theruthgroup.com

Cornerstone Pharmaceuticals Presents Non-Small Cell Lung Cancer Data for CPI-613 at 2014 Special Conference of American Association for Cancer Research

CRANBURY, NEW JERSEY (February 28, 2014) – Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that pre-clinical non-small cell lung cancer data of its first-in-class cancer metabolism targeted therapeutic, CPI-613, was presented by Dr. Candida Perera during a poster presentation on Thursday, February 27, 2014, at the 2014 special conference of the American Association for Cancer Research (AACR), titled “Cellular Heterogeneity in the Tumor Microenvironment,” in San Diego, CA.

The poster, titled, “Heterogeneous Response of H460 Non-Small Lung Carcinoma Cells to CPI-613, a Novel Compound That Selectively Alters Tumor Energy Metabolism” presents data that assessed the phenotypic heterogeneity of the H460 cell line following treatment with CPI-613.

CPI-613 is a first-in-class agent that induces cancer-specific inhibition of pyruvate dehydrogenase (PDH) and alpha ketoglutarate dehydrogenase (KGDH), key mitochondrial enzymes involved in fueling cancer cell metabolism. Disruption of PDH and KGDH function cuts off the tumor’s energy supply and starves the cancer cell, leading to cancer cell death. CPI-613 is currently being evaluated in Phase I, I/II and II human clinical trials in solid tumors and hematological malignancies.

CPI-613 is the lead drug candidate from Cornerstone's proprietary Altered Energy Metabolism Directed (AEMD) platform. Cornerstone’s AEMD drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential bioenergetic differences are linked to critical pathways, particularly those that support cancer cell growth and development.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company’s founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer



research and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. www.cornerstonepharma.com.

###

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.